Legislators
Bills
Statements
Lobbying
Travel
- Bills
- S.RES.97
S.RES.97: A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
About This Bill
- This bill was introduced in the 113th Congress
- This bill is primarily about health
- Introduced April 15, 2013
- Latest Major Action April 15, 2013
Bill Sponsor
Bill Cosponsors
3 (1 Democrat, 2 Republicans)
Bill Summary
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
(Source: Library of Congress)
Bill Actions
Date | Description |
---|---|
April 15, 2013 |
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
|
April 15, 2013 |
Introduced in the Senate by Tom Coburn (R-Okla.) |